ESLA Estrella Immunopharma, Inc.
Listings ·
Nasdaq notified Estrella on August 17, 2026 that its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance. Its year-end 2025 cash was $1.4 million.
Nasdaq sent two letters on September 23, 2025 closing both matters. The company had been notified of the deficiencies in April and August.
Nasdaq told Estrella on August 1, 2025 that its market value of listed securities fell below the $35,000,000 minimum. It has until January 28, 2026 to regain compliance, and its annual report for the year ended June 30, 2024 carried a going-concern warning.
| Line | FY2025 | FY ended Jun 30, 2024 |
|---|---|---|
| Research and development | $10.2 million | $4.1 million |
| Net income (loss) | -$13.1 million | -$7.3 million |
| Cash from operations | -$1.8 million | -$16.1 million |
| Cash and equivalents | $1.4 million | $4.2 million |
Our latest story on this, dated Aug 7, 2025: "Estrella Immunopharma gets Nasdaq deficiency notice on $35,000,000 market value requirement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 7, 2025: "Estrella Immunopharma gets Nasdaq deficiency notice on $35,000,000 market value requirement". The story links the filing or release it is based on. Read the story.
Estrella Immunopharma, Inc. trades under the ticker ESLA on NASDAQ.
Estrella Immunopharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Estrella Immunopharma, Inc. is 1844417. Its filings are on SEC EDGAR.
43,497,864 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Estrella Immunopharma, Inc. under United States.
Our directory classifies Estrella Immunopharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Estrella Immunopharma, Inc. is US2975841048.
aibio.space lists Estrella Immunopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Estrella Immunopharma, Inc. reported a net loss of $13.1 million for the fiscal year ended Dec 31, 2025, and used $1.8 million of cash in operations, per its annual report to the SEC.
$10.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$100,000 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Estrella Immunopharma, dated Aug 21, 2026: "Estrella Immunopharma gets Nasdaq minimum bid price notice, has until February 16, 2027 to comply". Nasdaq notified Estrella on August 17, 2026 that its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance. Its year-end 2025 cash was $1.4 million. Source.
From our story of Aug 21, 2026: The 10-K states that recurring losses and the need for more financing raise substantial doubt about the company's ability to continue as a going concern, and that it will need substantial additional funding. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio